603259 药明康德
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入45,537,43138.59%45,456,16639,241,43140,340,80739,354,778
减:营业总成本25,611,14520.49%29,148,15527,342,26828,708,59129,800,811
    其中:营业成本20,856,72818.92%23,801,43522,964,51523,728,80024,677,217
               财务费用328,79072.46%398,191(786,684)(338,119)(247,968)
               资产减值损失(89,141)-78.26%(541,556)(1,236,258)(156,509)(175,951)
公允价值变动收益164,294-577.10%(137,098)186,958(37,809)770,079
投资收益3,970,958-3.11%8,588,017604,162233,849187,949
    其中:对联营企业和合营企业的投资收益215,440-51.11%452,582245,065(67,560)(46,271)
营业利润24,070,46659.77%23,930,08411,580,17511,872,28610,652,249
利润总额24,049,49059.93%23,906,15111,539,81211,831,99110,618,476
减:所得税费用4,544,06860.52%4,573,0851,972,0722,131,7311,715,866
净利润19,505,42359.80%19,333,0669,567,7409,700,2608,902,611
减:非控股权益107,119-18.03%182,483117,43193,51188,898
股东净利润19,398,30460.64%19,150,5829,450,3089,606,7498,813,713

市场价值指针
每股收益 (元) *6.66056.71%6.7003.2803.2703.010
每股派息 (元) *0.510-27.14%2.2790.9820.9900.893
每股净资产 (元) *31.91033.39%26.71520.30218.57015.737
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容